American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the United States.
Betacoronavirus
/ drug effects
COVID-19
Cell- and Tissue-Based Therapy
/ methods
Coronavirus Infections
/ diagnosis
Disease Management
Hematopoietic Stem Cell Transplantation
Humans
Hydroxychloroquine
/ therapeutic use
Immunization, Passive
Inpatients
Outpatients
Pandemics
Patient Safety
Pharmacy Service, Hospital
/ organization & administration
Pneumonia, Viral
/ diagnosis
Practice Guidelines as Topic
Practice Patterns, Physicians'
/ statistics & numerical data
Public Opinion
SARS-CoV-2
Societies, Medical
Telemedicine
/ methods
United States
/ epidemiology
COVID-19 Drug Treatment
COVID-19 Serotherapy
COVID-19
Cellular therapy
Coronavirus
HCT
Pharmacist
Pharmacy
Journal
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
30
03
2020
revised:
04
04
2020
accepted:
06
04
2020
pubmed:
20
4
2020
medline:
3
6
2020
entrez:
20
4
2020
Statut:
ppublish
Résumé
The coronavirus-19 (COVID-19) pandemic poses a significant risk to patients undergoing hematopoietic stem cell transplantation (HCT) or cellular therapy. The American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Steering Committee aims to provide pharmacy practice management recommendations for how to transition clinical HCT or cellular therapy pharmacy services using telemedicine capabilities in the inpatient and outpatient settings to maintain an equivalent level of clinical practice while minimizing viral spread in a high-risk, immunocompromised population. In addition, the Steering Committee offers clinical management recommendations for COVID-19 in HCT and cellular therapy recipients based on the rapidly developing literature. As the therapeutic and supportive care interventions for COVID-19 expand, collaboration with clinical pharmacy providers is critical to ensure safe administration in HCT recipients. Attention to drug-drug interactions (DDIs) and toxicity, particularly QTc prolongation, warrants close cardiac monitoring and potential cessation of concomitant QTc-prolonging agents. Expanded indications for hydroxychloroquine and tocilizumab have already caused stress on the usual supply chain. Detailed prescribing algorithms, decision pathways, and specific patient population stock may be necessary. The COVID-19 pandemic has challenged all members of the healthcare team, and we must continue to remain vigilant in providing pharmacy clinical services to one of the most high-risk patient populations while also remaining committed to providing compassionate and safe care for patients undergoing HCT and cellular therapies.
Identifiants
pubmed: 32305359
pii: S1083-8791(20)30214-7
doi: 10.1016/j.bbmt.2020.04.005
pmc: PMC7162779
pii:
doi:
Substances chimiques
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1043-1049Informations de copyright
Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Références
Antiviral Res. 2019 Sep;169:104541
pubmed: 31233808
Nat Rev Rheumatol. 2020 Mar;16(3):155-166
pubmed: 32034323
J Med Chem. 2017 Mar 9;60(5):1648-1661
pubmed: 28124907
JAMA. 2007 Jul 11;298(2):187-93
pubmed: 17622600
Drug Metab Dispos. 2003 Jun;31(6):748-54
pubmed: 12756207
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Clin Infect Dis. 2020 Apr 15;70(9):1837-1844
pubmed: 31925415
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Nephron. 1993;65(2):333
pubmed: 8247209
J Pharmacol Exp Ther. 2018 Jun;365(3):447-459
pubmed: 29438998
Rheumatol Int. 2012 Sep;32(9):2601-4
pubmed: 22451032
Arthritis Care Res (Hoboken). 2018 Mar;70(3):481-485
pubmed: 28556555
Nephron. 1992;62(1):108-9
pubmed: 1436274
J Natl Compr Canc Netw. 2020 Mar 20;:1-4
pubmed: 32197238
Hong Kong Med J. 2003 Dec;9(6):399-406
pubmed: 14660806
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
JAMA. 2003 Jun 4;289(21):2801-9
pubmed: 12734147
Open Forum Infect Dis. 2020 Mar 23;7(4):ofaa105
pubmed: 32284951
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Br J Clin Pharmacol. 1988 Sep;26(3):303-13
pubmed: 3179169
N Engl J Med. 2003 May 15;348(20):1986-94
pubmed: 12682352
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Antiviral Res. 2006 Sep;71(2-3):397-403
pubmed: 16837072
Br J Clin Pharmacol. 1983 Apr;15(4):471-9
pubmed: 6849784
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565
Cell Discov. 2020 Mar 18;6:16
pubmed: 32194981